Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$1.33
+16.7%
$0.67
$0.11
$3.91
$43.21M11.0820.90 million shs6.90 million shs
PTEIQ
PolarityTE
$0.15
$0.05
$0.09
$1.24M0.9227,292 shs313 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$8.05
-4.7%
$8.38
$6.15
$905.52
$6.68M1.4103,966 shs13,003 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$1.12
-6.7%
$1.78
$1.10
$14.83
$3.65M1.87963,686 shs378,765 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00%+58.31%+456.10%+591.75%+113,999,900.00%
PTEIQ
PolarityTE
0.00%0.00%0.00%+4.10%-8.13%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.00%+0.88%+12.61%-35.47%-99.97%
Soligenix Inc. stock logo
SNGX
Soligenix
0.00%-11.76%-37.82%-35.83%-43.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/AN/AN/AN/A
PTEIQ
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
2.0139 of 5 stars
3.54.00.00.00.60.00.6
Soligenix Inc. stock logo
SNGX
Soligenix
1.476 of 5 stars
0.05.00.00.02.60.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00
N/AN/AN/A
PTEIQ
PolarityTE
0.00
N/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.003,378.26% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTEIQ, RNAZ, SNGX, and KLTO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2025
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/A$0.04 per shareN/A
PTEIQ
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A($54.96) per shareN/A
Soligenix Inc. stock logo
SNGX
Soligenix
$120K30.43N/AN/A$1.64 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-$6.15M-$0.36N/AN/AN/A-1,779.01%-275.01%N/A
PTEIQ
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%N/A
Soligenix Inc. stock logo
SNGX
Soligenix
-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)

Latest PTEIQ, RNAZ, SNGX, and KLTO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
5/15/2025Q1 2025
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.08N/A-$0.08N/AN/A
5/9/2025Q1 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/A
PTEIQ
PolarityTE
N/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A
0.29
0.29
PTEIQ
PolarityTE
N/A
4.11
4.11
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
5.20
5.20
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.85
1.85

Institutional Ownership

CompanyInstitutional Ownership
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
20.07%
PTEIQ
PolarityTE
11.75%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%

Insider Ownership

CompanyInsider Ownership
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
26.70%
PTEIQ
PolarityTE
5.40%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
Soligenix Inc. stock logo
SNGX
Soligenix
3.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A32.49 million23.82 millionN/A
PTEIQ
PolarityTE
607.32 million6.99 millionNot Optionable
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
9830,000832,000Not Optionable
Soligenix Inc. stock logo
SNGX
Soligenix
203.26 million3.16 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Klotho Neurosciences stock logo

Klotho Neurosciences NASDAQ:KLTO

$1.33 +0.19 (+16.67%)
As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

PolarityTE NASDAQ:PTEIQ

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$8.05 -0.40 (-4.73%)
As of 04:00 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.12 -0.08 (-6.67%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 0.00 (0.00%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.